The IBD therapeutic revolution started with a monoclonal antibody directed against tumor necrosis factor (TNF)-α termed antibody cA2 (now known as infliximab) in 1995 [4], one of the few drugs other than corticosteroids that achieved good efficacy in moderate-to-severe disease. Here, TNF is linked to inflammatory bowel disease.